CUE Stock Price History and Quote Analysis Insights for Investors
Cue Biopharma, Inc.
Stock Price Today
Cue Biopharma, Inc. (CUE) stock declined over -10.05%, trading at $0.94 on NASDAQ, down from the previous close of $1.05. The stock opened at $1.03, fluctuating between $0.94 and $1.03 in the recent session.
Stock Snapshot
Stock Price History Chart
Contact Details
About Company
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target and activate antigen-specific T cells for human papilloma virus-driven cancers. The company offers CUE-102, a fusion protein biologic to target and activate antigen-specific T cells to fight cancers; CUE-103 a CUE-100 series Immuno-STAT targeting the KRAS G12V mutation, including colorectal carcinoma, lung cancer, and pancreatic cancer; CUE-200 that focuses on cell surface receptors, including CD80 and/or 4-1BBL to address T cell exhaustion associated with chronic infections; and CUE-300 and CUE-400 framework to target various autoimmune diseases. Cue Biopharma, Inc. has collaboration agreements with Merck Sharp & Dohme Corp. for the research and development of its proprietary biologics that target various autoimmune disease indications; LG Chem Life Sciences for the development of Immuno-STATs focused on the field of oncology; and Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Company Information
| Employees | 53 |
| Beta | 1.8 |
| Sales or Revenue | $5.49M |
| 5Y Sales Change% | 1.114% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently Asked Questions
Cue Biopharma, Inc. (NASDAQ: CUE) stock price is $0.94 in the last trading session. During the trading session, CUE stock reached the peak price of $1.03 while $0.94 was the lowest point it dropped to. The percentage change in CUE stock occurred in the recent session was -10.05% while the dollar amount for the price change in CUE stock was -$0.11.
The NASDAQ listed CUE is part of Biotechnology industry that operates in the broader Healthcare sector. Cue Biopharma, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Dr. Ronald D. Seidel III, Ph.D.
Co-Founder
Dr. Anish Suri Ph.D.
Pres & Chief Scientific Officer
Dr. Matteo Levisetti M.D.
Chief Medical Officer
Mr. Daniel R. Passeri J.D., M.Sc., MSc.
Chief Executive Officer & Director
Ms. Kerri-Ann Millar
Chief Financial Officer
George B. Zavoico Ph.D.
Vice President of Investor Relations & Corporation Devel.
Mr. Colin G. Sandercock J.D., MSE
Senior Vice President, Gen. Counsel & Sec.
Dr. Kenneth J. Pienta M.D.
Acting Chief Medical Officer
Dr. Steven C. Almo
Co-Founder and Chairman of Scientific & Clinical Advisory Board
Dr. Rodolfo J. Chaparro
Co-Founder & Senior Advisor
Ms. Patricia Nasshorn
Chief Bus. Officer
CUE's closing price is 108.89% higher than its 52-week low of $0.45 where as its distance from 52-week high of $3.20 is -70.62%.
Number of CUE employees currently stands at 53.
Official Website of CUE is: https://www.cuebiopharma.com
CUE could be contacted at phone 617 949 2680 and can also be accessed through its website. CUE operates from 21 Erie Street, Cambridge, MA 02139, United States.
CUE stock volume for the day was 480.32K shares. The average number of CUE shares traded daily for last 3 months was 785.07K.
The market value of CUE currently stands at $59.55M with its latest stock price at $0.94 and 63.35M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2024 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com